Because FGF21 provides a downstream mechanism contributing to several metabolic interventions and given its direct clinical application for the treatment of fatty liver and other metabolic diseases, these findings may have broad implications for the targeted application of nutritional and pharmacological treatments for metabolic disease. The gene discussed is FGF21; the disease is Hepatic steatosis.